As per indicated here the agreement is:
"Basque biotechnology company Progenika Biopharma, specialised in the development of personal medicine technology, has granted Grifols exclusive worldwide distribution rights for its BLOODchip® molecular biology product."
"For Victor Grifols, President and CEO of Grifols “this agreement will allow us to strengthen our Diagnostic Division and consolidate our global position in the field of blood grouping with a new innovative tool that increases transfusion safety.”
Grifols was recently listed as part of the Critical Foreign Dependencies Initiative revelated by Wikileaks.
"Basque biotechnology company Progenika Biopharma, specialised in the development of personal medicine technology, has granted Grifols exclusive worldwide distribution rights for its BLOODchip® molecular biology product."
"For Victor Grifols, President and CEO of Grifols “this agreement will allow us to strengthen our Diagnostic Division and consolidate our global position in the field of blood grouping with a new innovative tool that increases transfusion safety.”
Grifols was recently listed as part of the Critical Foreign Dependencies Initiative revelated by Wikileaks.
No comments:
Post a Comment